Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1424P - Landscape of germline mutations in Chinese patients with gastric cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Gastric Cancer

Presenters

Yujian Zeng

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

Y. Zeng1, H. Zhang2, C. Shi1, T. Zhang1, G. Yang3, Z. Wu1, Y. Shi1, R. Chui1, L. Geng4, W. Duan2, H. Luo1

Author affiliations

  • 1 Gastrointestinal And Hernia Surgery, First Affiliated Hospital of Kunming Medical University, 650032 - Kunming/CN
  • 2 The Medical Department, 3D Medicines Inc., 201114 - Shanghai/CN
  • 3 General Surgery, Xiangyun County People's Hospital of Yunnan Province, 672100 - Dali/CN
  • 4 First Affiliated Hospital Of Kunming Medical University, First Affiliated Hospital of Kunming Medical University, 650032 - Kunming/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1424P

Background

Although most gastric cancers (GC) are sporadic, but familial cases also occur in GC such as hereditary diffuse GC and familial intestinal GC. Most familial patients with GC are probably due to heritable pathogenic mutations. Among these familial GC, only hereditary diffuse GC is genetically explained which was known as to be caused by germline alterations of CDH1. Herein, we evaluated the genetic characteristic that mainly focused on germline mutation in Chinese patients with GC.

Methods

The Formalin-Fixed Paraffin-Embedded (FFPE) tissues from GC patients who have underwent next generation sequencing (NGS) from February, 2018 to December, 2020 in 3DMed Clinical Laboratory Inc. (a College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory) were analyzed. The single nucleotide variants (SNVs), germline mutation, copy number variants (CNVs) and gene rearrangements data of these patients were analyzed.

Results

NGS results revealed that there were 57.8% (1069/1850) patients carry germline mutation, 13.46% (248/1850) were germline deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM), and except for benign, likely benign, and variant of unknown clinical significance, 2.8% (52/1850) patients were pathogenic mutation in germline. Among the pathogenic germline mutation, the top germline mutation genes were BRCA2 0.70% (13/1850), ATM 0.70% (13/1850), CHEK2 0.27% (5/1850), PALB2 0.27% (5/1850), CDH1 0.22% (4/1850), MUTYH 0.22% (4/1850), MSH1 0.11% (2/1850), MSH6 0.11% (2/1850), PMS2 0.11% (2/1850), BRCA1 0.11% (2/1850), TSC2 0.11% (2/1850).

Conclusions

Although the incidence of familial gastric cancer is low, the spectrum of germline mutations related to genetic risk is extensive. It is necessary to accurately manage the genetic risk of gastric cancer,consideration should be given to testing more than CDH1 in the germline mutation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.